Abstract Details

Title Comorbidity Profile of Spasticity within a Cohort of Post-Stroke Survivors

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P07 - (-)

Poster/Presentation
Number 229

Objective

Background BACKGROUND: While multiple comorbidities have been associated with stroke, there is a relative paucity of literature on comorbidity rates in the PSS population.

Design/Methods DESIGN/METHODS: Data from the 2005 Greater Cincinnati Northern Kentucky Stroke Study (GCNKSS), a 5-county longitudinal study designed to characterize a stroke population (defined as verified ischemic stroke), were utilized. PSS was defined as patient-reported spasticity at 3-month or 1-year, while no-PSS was defined as no report of spasticity at either assessment. Baseline comorbidities, which were collected via direct patient interview or chart extraction on post-stroke day 1, were investigated for an association with subsequent spasticity. Groups were compared using chi-square or Fisher's exact t-test, as appropriate.

Results RESULTS: Of the 236 patients who completed the initial interview and reported spasticity status at subsequent assessments, 78(33%) reported spasticity. Demographic data revealed that PSS patients were younger, more likely to be non-Caucasian, and had higher NIHSS. Comorbidities occurring at ?10% in either group (PSS vs no-PSS; no reported p-value indicates non-significance) were ischemic stroke (21% vs 18%), TIA (18% vs 8%, p=0.03), hypertension (83% vs 70%, p=0.03), heart disease (23% vs 27%), heart attack (64% vs 57%), carotid artery disease (18% vs 8%; p=0.01), seizure (10% vs 4%), pain disorders (53% vs 58%), depression (33% vs 21%; p=0.04), migraine (23% vs 6%;), neuropathy (74% vs 77%), diabetes (41% vs 32%), cancer (13% vs 14%), visual loss/blindness (17% vs 13%), and infection (<2 weeks) (15% vs 18%).

Conclusions CONCLUSIONS: Our data provides the first assessment of comorbidities associated with PSS in a US cohort. Comorbidities identified with PSS are useful in identifying patients at risk for spasticity development and hopefully, will help with the development of preventative measures to reduce burden.

Authors/Disclosures
Theodore Wein, MD (Montreal General Hospital) PRESENTER	No disclosure on file
Aubrey Adams, PhD	Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
Federica Agosta (San Raffaele Scientific Institute)	Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
	No disclosure on file
Patrick J. Gillard, PharmD, MS	Mr. Gillard has received personal compensation for serving as an employee of AbbVie. Mr. Gillard has stock in AbbVie.
Kathleen Alwell	No disclosure on file
	No disclosure on file
Daniel Woo, MD, FAAN (University at Buffalo)	The institution of Dr. Woo has received research support from NIH.
Pooja Khatri, MD, FAAN (Univ of Cincinnati/Dept of Neuro)	The institution of Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lumosa. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bayer. The institution of Dr. Khatri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Diamedica. Dr. Khatri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Basking Biosciences. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Khatri has received research support from Cerenovus. Dr. Khatri has received publishing royalties from a publication relating to health care.
Matthew L. Flaherty, MD	Dr. Flaherty has received personal compensation for serving as an employee of Sense Diagnostics, Inc. Dr. Flaherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boeringher Engelheim. Dr. Flaherty has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Flaherty has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion. Dr. Flaherty has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various law firms. Dr. Flaherty has stock in Sense Diagnostics, Inc. The institution of Dr. Flaherty has received research support from NINDS. Dr. Flaherty has received intellectual property interests from a discovery or technology relating to health care.
Opeolu Adeoye	No disclosure on file
Simona Ferioli, MD (UCMC)	Dr. Ferioli has nothing to disclose.
Joseph P. Broderick, MD, FAAN (University of Cincinnati)	The institution of Dr. Broderick has received research support from Novo Nordisk. Dr. Broderick has received publishing royalties from a publication relating to health care.
Dawn O. Kleindorfer, MD, FAAN (University of Michigan Department of Neurology)	Dr. Kleindorfer has nothing to disclose.
Brett M. Kissela, MD, MS, FAAN (University of Cincinnati Hospital)	The institution of Dr. Kissela has received research support from NIH/NINDS. Dr. Kissela has a non-compensated relationship as a Board Member with AHA Regional Board that is relevant to AAN interests or activities.

��ɫ��

��ɫ��